Press Release

Cyxone receives Intention to Grant from the European Patent Office for a unitary patent of T20K

October 9, 2023 08:38 (CEST)

Cyxone (publ), a biotech company in autoimmune diseases announces that the European Patent Office (EPO) has issued an intention to grant communication for a unitary patent of the divisional EP-Divisional Patent Application 18 172 126.7 entitled Cyclotides as immunosuppressive agents. The patent covers the protection of the drug candidate T20K that Cyxone licenses from the Medical University of Vienna and the University of Freiburg.

The European patent office announced that the patent application will be granted as a unitary patent as of November 1st, 2023, and will be valid in the countries that have ratified the UPC (Unitary Patent Court) agreement – at the moment 17 out of 39 member states of the European Patent Office’s cooperation.

The intention to grant communication is an official announcement from the patent office indicating that the patent application has reached the stage where the patent is about to be approved. When approved, the patent will be valid until 2032.

“Receiving this announcement from the EPO is very valuable. We chose this novel track with the T20K patent, and we are pioneering the new UPC system that came into force the June 1st, 2023. The intention of the UPC is to significantly expediate the patent process resulting in a faster procedure and reduced costs, which is very valuable for the innovation process. The ambition with the UPC is to enable patent protection in 25 EU member states with a single patent application. This is yet another important milestone in progressing the T20K project forward and we are pleased to receive this announcement which future-proofs the T20K development program,” says Carl-Magnus Högerkorp, CEO at Cyxone.


Carl-Magnus Högerkorp, CEO
Tel: +46 (0)70 781 88 12

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit

Open Press release